Clinical trial · Observational
DNA Methylation and the Increased Risk of Cervical Cancer Development
The Role of the Genital Tract Microbiota in Cervical Epithelial Cell DNA Methylation and the Increased Risk of Cervical Cancer Development
NCT06859151CI-TRIAL-00086780not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to investigate the correlation between reproductive tract microbiota and DNA methylation in cervical epithelial cells, as well as its impact on the development of cervical cancer, through a paired case-control clinical study
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Papillomavirus Infections | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Reproductive tract microbiota | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- control
- description
- HPV16(-) HPV18(-) TCT(-)
- interventionNames
- Other: Reproductive tract microbiota
- label
- Case group 1
- description
- HPV16(+) /HPV18(+) TCT(-) CIN\<2
- interventionNames
- Other: Reproductive tract microbiota
- label
- Case group 2
- description
- HPV16(+) /HPV18(+) TCT(+) CIN\<2
- interventionNames
- Other: Reproductive tract microbiota
- label
- Case group 3
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 15 Years
- Maximum age
- 50 Years
Show eligibility criteria text
Inclusion Criteria: 1. Aged 18-50 years old, with a history of sexual activity 2. HPV and TCT tests are performed concurrently in the gynecology clinic 3. Those with abnormal HPV and TCT test results undergo tissue pathological testing Exclusion Criteria: 1. Pregnant or breastfeeding 2. Patients with immunological disorders or severe autoimmune diseases, such as AIDS, SLE 3. Those who have had organ transplants or are currently using immunosuppressive agents 4. Use of vaginal douching within 48 hours before sample collection 5. Use of vaginal probiotics within one month before sample collection 6. Use of vaginal antibiotics or antifungal treatments within one month before sample collection 7. History of surgery related to cervical intraepithelial neoplasia (CIN), including but not limited to conization of the cervix, LEEP procedures, etc. 8. Blood samples (avoid sampling during menstruation), insufficient remaining sample volume to support subsequent analysis needs, and samples not stored as required.
References
Publications (0)
Data not yet available
No reference posted for this study.